A woman with atypical hemolytic uremic syndrome (aHUS) successfully underwent a second kidney transplant as treatment with Soliris…
Andrea Lobo
Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto, in drug addiction, studying neuronal plasticity induced by amphetamines. As a research scientist for 19 years, Andrea participated in academic projects in multiple research fields, from stroke, gene regulation, cancer, and rare diseases. She authored multiple research papers in peer-reviewed journals. She shifted towards a career in science writing and communication in 2022.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Andrea Lobo
Treatment with Ultomiris (ravulizumab) led to both rapid and long-lasting improvements in people with atypical hemolytic uremic syndrome…
Eculizumab and ravulizumab — treatments for atypical haemolytic uremic syndrome (aHUS), available in the U.S. as Soliris and biosimilars,…
A 21-year-old man with atypical hemolytic uremic syndrome (aHUS) associated with Castleman disease improved after receiving treatment with iptacopan…
The case of a 29-year-old woman who developed pregnancy-associated atypical hemolytic uremic syndrome (aHUS) along with uncommon lung complications after…
People with atypical hemolytic uremic syndrome (aHUS) who completed self-assessments for a study scored lower on measures of physical…
A 26-year-old woman who developed pregnancy-associated atypical hemolytic uremic syndrome (p-aHUS) successfully recovered following treatment with Soliris (eculizumab), according to a case…
A 29-year-old woman in the U.S. showed signs of atypical hemolytic uremic syndrome (aHUS) and a C2 gene mutation,…
Switching from Soliris (eculizumab) to Ultomiris (ravulizumab) is a safe and effective treatment strategy for people with…
Atypical hemolytic uremic syndrome (aHUS) may be triggered by acute inflammation of the pancreas, or pancreatitis, a team of…